Publicaciones en las que colabora con P. J. García Ruiz-Espiga (20)

2022

  1. Clinical and structural brain correlates of hypomimia in early-stage Parkinson's disease

    European Journal of Neurology, Vol. 29, Núm. 12, pp. 3720-3727

2021

  1. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  2. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage

    Nature Communications, Vol. 12, Núm. 1

  3. Identification of sixteen novel candidate genes for late onset Parkinson’s disease

    Molecular Neurodegeneration, Vol. 16, Núm. 1

  4. Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease

    Annals of Neurology, Vol. 90, Núm. 1, pp. 35-42

  5. Spanish expert consensus on the use of safinamide in Parkinson's disease

    Neurologia, Vol. 36, Núm. 9, pp. 666-672

2020

  1. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders

    Brain, Vol. 143, Núm. 9, pp. 2771-2787

  2. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

    The Lancet Neurology, Vol. 18, Núm. 12, pp. 1091-1102

  2. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

    npj Parkinson's Disease, Vol. 5, Núm. 1

  3. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability

    npj Parkinson's Disease, Vol. 5, Núm. 1

  4. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease

    Movement Disorders, Vol. 34, Núm. 9, pp. 1333-1344

  5. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2018

  1. LRP10 in α-synucleinopathies

    The Lancet Neurology

  2. Mitos y evidencias en el empleo de la toxina botulínica: Neurofarmacología y distonías

    Revista de Neurologia, Vol. 66, Núm. 5, pp. 163-172

2013

  1. Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)

    Neurologia, Vol. 28, Núm. 8, pp. 503-521

  2. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II

    Neurologia, Vol. 28, Núm. 9, pp. 558-583

2012

  1. levodopa en el tratamiento de la enfermedad de parkinson: Mitos y realidades

    Revista de Neurologia, Vol. 55, Núm. 11, pp. 669-688

2010

  1. Efficacy and safety of pallidal stimulation in primary dystonia: Results of the Spanish multicentric study

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 81, Núm. 1, pp. 65-69

2009

  1. Documento de consenso sobre estimulación cerebral profunda en la enfermedad de Parkinson

    Revista de Neurologia